Michael Warren
Family · Deridder, LANPI 1598114423
Payments from drug & device makers
Across 175 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$670
- Novo Nordisk$443
- Boehringer Ingelheim$298
- AstraZeneca$263
- Supernus Pharmaceuticals, Inc.$246
- Abbott$183
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,154100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $670 |
| Novo Nordisk | 25 | $443 |
| Boehringer Ingelheim | 19 | $298 |
| AstraZeneca | 14 | $263 |
| Supernus Pharmaceuticals, Inc. | 7 | $246 |
| Abbott | 9 | $183 |
| Lilly USA, LLC | 9 | $139 |
| Otsuka America Pharmaceutical, Inc. | 6 | $121 |
| Pfizer | 6 | $111 |
| Amgen | 6 | $97 |
| Bayer | 4 | $74 |
| Exact Sciences | 4 | $74 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Novartis | 3 | $42 |
| Alkermes, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Ardelyx, Inc. | 2 | $35 |
| Cequr Corporation | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Gilead | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$3,154 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 207 | $280,500 |
| MounjaroTirzepatide | 52 | $87,323 |
| EliquisApixaban | 83 | $66,795 |
| JardianceEmpagliflozin | 88 | $66,224 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $59,841 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 36 | $56,941 |
| Xigduo XrDapaglifloz Propaned/Metformin | 60 | $51,457 |
| TrulicityDulaglutide | 32 | $48,494 |
| LinzessLinaclotide | 51 | $37,818 |
| FarxigaDapagliflozin Propanediol | 49 | $36,952 |
| RexultiBrexpiprazole | 15 | $32,585 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 42 | $25,944 |
| JanuviaSitagliptin Phosphate | 27 | $20,300 |
| XareltoRivaroxaban | 18 | $18,461 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $17,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $443 | $280,500207 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat, Stiolto Respimat, Trijardy Xr | $298 | $173,154205 claims |
| Lilly USA, LLCMounjaro, Trulicity | $139 | $135,81784 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $263 | $70,546112 claims |
| PfizerEliquis | $111 | $66,79583 claims |
| AbbVieLinzess | $670 | $37,81851 claims |
| MerckJanuvia, Janumet | $12 | $32,84942 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $121 | $32,58515 claims |
| Astellas Pharma US IncVeozah | $17 | $6,08911 claims |
| Sanofi-aventis U.S. LLCLantus | $42 | $2,10824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.
Other family in Deridder
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.